In this paper the authors present a case of malignant clear-cell hidradenoma developed on the dorsum of the hand. This is only the eleventh complete report in the literature, including follow-up, and only the third to include necropsy. It is the first to find both lung and myocardial metastases. The tumor was very invasive and was treated first by wide surgical excision and radical node dissection, and when the tumor recurred, amputation of the arm was done. The world literature was carefully reviewed and compared with this case. Owing to the already known failure of radiotherapy, and since chemotherapy was not successful in our patient, the authors advise early aggressive surgery, including block dissection of the regional nodes, and thereafter a careful follow-up.

Download full-text PDF

Source
http://dx.doi.org/10.1097/00006534-198708000-00027DOI Listing

Publication Analysis

Top Keywords

malignant clear-cell
8
clear-cell hidradenoma
8
hidradenoma paper
4
paper authors
4
authors case
4
case malignant
4
hidradenoma developed
4
developed dorsum
4
dorsum hand
4
hand eleventh
4

Similar Publications

In renal cell carcinoma (RCC) patients with inferior vena cava (IVC) tumor thrombus, neoadjuvant therapy could alleviate the burden of tumor thrombus, enhance the safety and feasibility of surgical resection, and improve patient prognosis. The combination of tislelizumab and axitinib has demonstrated efficacy in the treatment of advanced RCC. Our study aimed to evaluate the efficacy and safety in the neoadjuvant therapy setting of tislelizumab and axitinib in RCC patients with IVC tumor thrombus.

View Article and Find Full Text PDF

Renal cell carcinoma (RCC) is one of the most common malignancies in the urinary system, and clear cell renal cell carcinoma (ccRCC) is the most common subtype. MYBL2 has been reported to be overexpressed in various tumors and associated with poor prognosis in patients, but its biological role in ccRCC remains unclear. In this study, we investigated the mRNA and protein expression levels of MYBL2 in ccRCC samples and evaluated the prognostic value of MYBL2 using TCGA dataset.

View Article and Find Full Text PDF

Gamna-Gandy (GG) bodies are sclerosiderotic nodules composed of iron pigment and calcium, that have been described predominantly in the spleens of patients with sickle cell disease. Their formal depiction in the kidney is mainly limited to case reports and small series. We aimed to investigate the incidence of GG bodies and associated clinicopathologic features in consecutive nephrectomies performed for renal tumors.

View Article and Find Full Text PDF

[Histomorphologically defined renal cell carcinomas 2025 : Current WHO classification and emerging future subtypes].

Pathologie (Heidelb)

January 2025

Institut für Pathologie, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Krankenhausstraße 8-10, 91054, Erlangen, Deutschland.

Background: The latest edition of the WHO classification of urinary and male genital tumours was published in 2022. The revision was based on the newest scientific literature. This article summarizes the updated recommendations regarding the classification of histomorphologically defined tumours.

View Article and Find Full Text PDF

Objectives: To analyze the association of CHMP2B expression level of with clinicopathological characteristics and prognosis of clear cell renal cell carcinoma (CRCC) and the possible role of CHMP2B in tumorigenesis and progression of CRCC.

Methods: RNAseq data of CRCC were downloaded from the TCGA database for analysis of CHMP2B expression levels in tumor and adjacent tissues and their correlation with clinicopathological characteristics of the patients. Survival outcomes of the patients with high and low CHMP2B expressions were analyzed using the Kaplan-Meier model, and the COX risk regression model was used for identifying the prognostic factors of the patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!